Fanghang Ye

Mr. Fanghang Ye


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SLShenghao Li
Shenghao Li
LHLiyuan Hao
Liyuan Hao
JDJiali Deng
Jiali Deng
JZJunli Zhang
Junli Zhang
FYFei Yu
Fei Yu
XHXiaoyu Hu
Xiaoyu Hu
Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for over 250 million cases of chronic liver infections, leading to conditions such as liver inflammation, cirrhosis and hepatocellular carcinoma (HCC). Sodium taurocholate co-transporting polypeptide (NTCP) is a transmembrane protein highly expressed in human hepatocytes and functions as a bile acid (BA) transporter. NTCP has been identified as the receptor that HBV and its satellite virus, hepatitis delta virus (HDV), use to enter hepatocytes. HBV entry into hepatocytes is tightly regulated by various signaling pathways, and NTCP plays an important role as the initial stage of HBV infection. NTCP acts as an initiation signal, causing metabolic changes in hepatocytes and facilitating the entry of HBV into hepatocytes. Thus, a comprehensive understanding of NTCP’s role is crucial. In this review, we will examine the regulatory mechanisms governing HBV pre-S1 binding to liver membrane NTCP, the role of NTCP in HBV internalization, and the transcriptional and translational regulation of NTCP expression. Additionally, we will discuss clinical drugs targeting NTCP, including combination therapies involving NTCP inhibitors, and consider the safety of NTCP as a therapeutic target.

1 October 2024 in Clinical Nutrition
Verified
Journal Article
Open access
FYFanghang Ye
Fanghang Ye
YHYucheng Huang
Yucheng Huang
LZLiang Zeng
Liang Zeng
NLNa Li
Na Li
LHLiyuan Hao
Liyuan Hao
XHXiaoyu Hu
Xiaoyu Hu
The ketogenic diet or exogenous supplementation with 3-hydroxybutyrate (3HB) is progressively gaining recognition as a valuable therapeutic or health intervention strategy. However, the effects of 3HB on cancers have been inconsistent in previous studies. This study aimed to comprehensively investigate the causal effects of circulating 3HB levels on 120 cancer phenotypes, and explore the 3HB mediation effect between liver fat accumulation and cancers. Univariate Mendelian randomization (UVMR) was used in this study to investigate the causal impact of circulating 3HB levels on cancers. We conducted meta-analyses for 3HB-cancer associations sourced from different exposure data. In multivariate MR(MVMR), the body mass index, alcohol frequency and diabetes were included as covariates to investigate the independent effect of 3HB on cancer risk. Additionally, utilizing mediation MR analysis, we checked the potential mediating role of 3HB in the association between liver fat and cancer. Integrating findings from UVMR and MVMR, we observed that elevated circulating 3HB levels were associated with reduced risk of developing diffuse large B-cell lymphoma(DLBCL) (OR[95%CI] = 0.28[0.14-0.57] p = 3.92e-04), biliary malignancies (OR[95%CI] = 0.30[0.15-0.60], p = 7.67e-04), hepatocellular carcinoma(HCC) (OR[95%CI] = 0.25[0.09-0.71], p = 9.33e-03), primary lymphoid and hematopoietic malignancies (OR[95%CI] = 0.76[0.58-0.99], p = 0.045). Further UVMR analysis revealed that an increase in the percent liver fat was associated with reduced 3HB levels (Beta[95%CI] = -0.073[-0.122∼-0.024], p = 0.0034) and enhanced susceptibility to HCC (OR[95%CI] = 13.9[9.76-19.79], p = 3.14e-48), biliary malignancies (OR[95%CI] = 4.04[3.22-5.07], p = 1.64e-33), nasopharyngeal cancer (OR[95%CI] = 3.26[1.10-9.67], p = 0.03), and primary lymphoid and hematopoietic malignancies (OR[95%CI] = 1.27[1.13-1.44], p = 1.04e-4). Furthermore, 3HB fully mediated the effect of liver fat on susceptibility to DLBCL (OR[95%CI] = 1.076[1.01-1.15], p = 0.034). Circulating 3HB is associated with a reduced susceptibility to developing DLBCL, HCC, biliary malignancies, and primary lymphoid and hematopoietic malignancies. The impaired ketogenesis induced by metabolic-dysfunction associated fatty liver disease (MAFLD) contributes to risk of DLBCL.

19 May 2025 in Experimental Gerontology
Verified
Journal Article
Open access
FYFanghang Ye
Fanghang Ye
YHYucheng Huang
Yucheng Huang
NLNa Li
Na Li
LHLiyuan Hao
Liyuan Hao
JDJiali Deng
Jiali Deng
XHXiaoyu Hu
Xiaoyu Hu
The associations between type 2 diabetes (T2D) and neurological as well as psychiatric disorders have garnered growing interest. Previous evidence has indicated a correlation between the cerebral cortex and these conditions. However, the causal direction between the cerebral cortex and T2D remains ambiguous. We conducted a cerebral cortex-focused systematic Mendelian randomization (MR) study based on multiple data sourced from genome-wide association studies and expression quantitative trait locus. The surficial area (SA) of Pars Opercularis and the thickness (TH) of the Supramarginal gyrus were found as significant contributors to the risk of T2D. Conversely, thickening in the Precentral area, Caudal Anterior Cingulate cortex, and banks of the Superior Temporal Sulcus, as well as SA amplification of the Precentral area, were associated with a reduced risk of T2D. There was no evidence of reverse causation. These alterations also have an impact on susceptibility to T2D complications. Combining the summary-data-based MR (SMR) analysis and colocalization analysis, we prioritized the expression of three causal genes in the cerebral cortex with genetic evidence for influencing T2D susceptibility. Elevated expression levels of NUDC and PACC1 increased susceptibility to T2D, whereas RAB29 expression exhibits an inverse association with T2D susceptibility. Mediation MR analysis revealed that TH of the Banks of the Superior Temporal Sulcus, SA of Precentral area, SA of Pars Opercularis, and SA of Supramarginal gyrus mediated the effect of RAB29 on T2D. Cross-tissue colocalization analysis demonstrated that the expression pattern of NUDC displayed brain tissue specificity. PACC1 and RAB29 also exhibited colocalization signals in several specific tissues beyond brain tissue. The phenome-wide association study suggested that these genes underscore the shared genetic burden of T2D with a range of disease phenotypes including mental disorders, cardiovascular disease, and malignancies. These findings underscore the novel role of the central nervous system in genetic liability to T2D and provide valuable clues for future mechanism studies.

16 June 2026 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
NLNa Li
Na Li
FYFanghang Ye
Fanghang Ye
FYFei Yu
Fei Yu
LHLiyuan Hao
Liyuan Hao
SLShenghao Li
Shenghao Li
XHXiaoyu Hu
Xiaoyu Hu

24 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FYFei Yu
Fei Yu
YZYue ZHU
Yue ZHU
NLNa Li
Na Li
QPQing Peng
Qing Peng
FYFanghang Ye
Fanghang Ye
XHXiaoyu Hu
Xiaoyu Hu
The sodium-taurocholate cotransporting polypeptide (NTCP) plays a critical dual role in liver function: maintaining bile acid (BA) enterohepatic circulation and acting as a receptor for the entry of hepatitis B and D viruses into hepatocytes. This review outlines the impact of various post-translational modifications (PTMs) of NTCP—including phosphorylation, oligomerization, ubiquitination, and glycosylation—on its dynamic regulatory network. These modifications coordinate the modulation of NTCP’s membrane localization, stability, conformational state, and protein interactions, precisely controlling its functions in BA uptake and viral invasion. Targeting this PTM network presents a promising strategy for next-generation therapies that selectively inhibit viral infection while preserving BA transport, overcoming the limitations of conventional inhibitors that indiscriminately disrupt virus–NTCP interactions. By synthesizing recent insights into NTCP PTM research, this article highlights its role as a central regulator of its bifunctional properties and reveals potential avenues for precision therapies in viral hepatitis, cholestasis, and related liver diseases. However, most existing evidence is derived from in vitro or cell-based models, whereas in vivo studies and clinical validation remain limited; thus, the translational feasibility of strategies targeting post-translational modifications of NTCP still requires further investigation.